1. Molecular landscape for risk prediction and personalized therapeutics of castration-resistant prostate cancer: at a glance
- Author
-
Jingang Jian, Xin’an Wang, Jun Zhang, Chenchao Zhou, Xiaorui Hou, Yuhua Huang, Jianquan Hou, Yuxin Lin, and Xuedong Wei
- Subjects
castration-resistant prostate cancer ,molecular signatures ,carcinogenic mechanisms ,personalized medicine ,medical systems biology ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Prostate cancer (PCa) is commonly occurred with high incidence in men worldwide, and many patients will be eventually suffered from the dilemma of castration-resistance with the time of disease progression. Castration-resistant PCa (CRPC) is an advanced subtype of PCa with heterogeneous carcinogenesis, resulting in poor prognosis and difficulties in therapy. Currently, disorders in androgen receptor (AR)-related signaling are widely acknowledged as the leading cause of CRPC development, and some non-AR-based strategies are also proposed for CRPC clinical analyses. The initiation of CRPC is a consequence of abnormal interaction and regulation among molecules and pathways at multi-biological levels. In this study, CRPC-associated genes, RNAs, proteins, and metabolites were manually collected and integrated by a comprehensive literature review, and they were functionally classified and compared based on the role during CRPC evolution, i.e., drivers, suppressors, and biomarkers, etc. Finally, translational perspectives for data-driven and artificial intelligence-powered CRPC systems biology analysis were discussed to highlight the significance of novel molecule-based approaches for CRPC precision medicine and holistic healthcare.
- Published
- 2024
- Full Text
- View/download PDF